ATYR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

9 Analyst Rating

Wall Street analysts forecast ATYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATYR is 8.00 USD with a low forecast of 1.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

7 Hold

0 Sell

Hold

Current: 0.000

Low

1.00

Averages

8.00

High

20.00

Current: 0.000

Low

1.00

Averages

8.00

High

20.00

Leerink

Faisal Khurshid

Outperform

maintain

$NULL

2025-09-15

Reason

Leerink

Faisal Khurshid

Price Target

$NULL

2025-09-15

maintain

Outperform

Reason

Leerink analyst Faisal Khurshid keeps an Outperform rating on aTyr Pharma after the company said the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint of steroid reduction. While aTyr plans to engage with the FDA on a potential path forward, Leerink's expectations are low given the primary endpoint miss and unclear relevance of KSQ-Lung score improvements alone, the analyst tells investors in a research note. Going into the readout, the firm expected a primary endpoint miss would see 80%-90% share downside. aTyr Pharma shares are down 82%, or $4.97, to $1.07 in early trading.

Cantor Fitzgerald

Overweight -> Neutral

downgrade

2025-09-15

Reason

Cantor Fitzgerald

Price Target

2025-09-15

downgrade

Overweight -> Neutral

Reason

Cantor Fitzgerald downgraded aTyr Pharma to Neutral from Overweight after the company announced that the Phase 3 pulmonary sarcoidosis trial for efzofitimod missed the primary endpoint of change in mean steroid dose from baseline at week 48. aTyr plans to engage with the FDA to determine the path forward, but the firm doesn't have much confidence in the path forward for efzo in pulmonary sarcoidosis, the analyst tells investors.

Leerink

Faisal Khurshid

Outperform

Market Perform

downgrade

$16 -> $1

2025-09-15

Reason

Leerink

Faisal Khurshid

Price Target

$16 -> $1

2025-09-15

downgrade

Outperform

Market Perform

Reason

Leerink analyst Faisal Khurshid downgraded aTyr Pharma to Market Perform from Outperform with a price target of $1, down from $16, after the company reported that the Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis failed to meet its primary endpoint. The firm had been positive heading into the \"highly binary\" readout, but tells investors \"we were wrong\" after topline results showed no statistically significant difference in steroid reduction. The firm isn't sure there is a path forward for efzo given the miss on the primary endpoint and unclear clinical relevance of quality-of-life improvement, the analyst added.

H.C. Wainwright

Buy -> Neutral

downgrade

2025-09-15

Reason

H.C. Wainwright

Price Target

2025-09-15

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded aTyr Pharma to Neutral from Buy without a price target after the company's Phase 3 EFZO-FIT study evaluating lead asset efzofitimod for the treatment of pulmonary sarcoidosis missed the primary endpoint. \"Many open questions remain regarding a path forward,\" the analyst tells investors in a research note. The firm cites the lack of regulatory visibility for the downgrade.

JonesResearch

Soumit Roy

Buy

Hold

downgrade

2025-09-15

Reason

JonesResearch

Soumit Roy

Price Target

2025-09-15

downgrade

Buy

Hold

Reason

JonesResearch analyst Soumit Roy downgraded aTyr Pharma to Hold from Buy without a price target after the Phase 3 EFZO-FIT trial failed to show a significant reduction in change from baseline in mean daily oral corticosteroid dose at week 48 with efzofitimod in patients with pulmonary sarcoidosis. The firm did not expect 40% of patients in the placebo arm to taper to 0mg of steroid at 48 weeks. Jones doubts the FDA will green light efzofitimod with the current dataset and removed the drug from the stock's valuation. aTyr shares could pull back further without a clear decision soon on the fate of its programs, the analyst tells investors in a research note.

Lucid Capital

Buy -> Neutral

downgrade

$11 -> $1

2025-09-15

Reason

Lucid Capital

Price Target

$11 -> $1

2025-09-15

downgrade

Buy -> Neutral

Reason

Lucid Capital downgraded aTyr Pharma to Neutral from Buy with a price target of $1, down from $11, after the Phase 3 EFZO-FIT trial failed to show a significant reduction in change from baseline in mean daily oral corticosteroid dose at week 48 with efzofitimod in patients with pulmonary sarcoidosis. While the data suggests clinical benefit on quality-of-life endpoints, the failure to achieve statistical significance on the primary endpoint \"complicates the regulatory path\" and the firm prefers to stay on the sidelines pending FDA discussions as it believes shares may remain range-bound until there is more clarity.

Valuation Metrics

The current forward P/E ratio for aTyr Pharma Inc (ATYR.O) is -1.33, compared to its 5-year average forward P/E of -2.80. For a more detailed relative valuation and DCF analysis to assess aTyr Pharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.80

Current PE

-1.33

Overvalued PE

-1.15

Undervalued PE

-4.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.38

Current EV/EBITDA

0.05

Overvalued EV/EBITDA

0.58

Undervalued EV/EBITDA

-3.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

479.05

Current PS

68.15

Overvalued PS

1486.81

Undervalued PS

-528.71

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 5978.67% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 5978.67% over the last month.

Sold

Bought

ATYR News & Events

Events Timeline

No data

News

7.0

2025-12-15PRnewswire

aTyr Pharma Faces Shareholder Lawsuit Investigation Over Phase 3 Trial Disclosures

7.0

2025-12-11Globenewswire

aTyr Pharma Faces Shareholder Derivative Claims Investigation Over Phase 3 Trial Disclosures

7.0

2025-12-09PRnewswire

aTyr Pharma Class Action Notice: Lead Plaintiff Deadline December 8

People Also Watch

Frequently Asked Questions

What is aTyr Pharma Inc (ATYR) stock price today?

The current price of ATYR is 0.7127 USD — it has decreased -1.65 % in the last trading day.

What is aTyr Pharma Inc (ATYR)'s business?

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

What is the price predicton of ATYR Stock?

What is aTyr Pharma Inc (ATYR)'s revenue for the last quarter?

aTyr Pharma Inc revenue for the last quarter amounts to 190.00K USD, decreased % YoY.

What is aTyr Pharma Inc (ATYR)'s earnings per share (EPS) for the last quarter?

aTyr Pharma Inc. EPS for the last quarter amounts to -0.26 USD, increased 13.04 % YoY.

What changes have occurred in the market's expectations for aTyr Pharma Inc (ATYR)'s fundamentals?

The market is revising Downward the revenue expectations for aTyr Pharma, Inc. (ATYR) for FY2025, with the revenue forecasts being adjusted by -89.53% over the past three months. During the same period, the stock price has changed by -32.76%.

How many employees does aTyr Pharma Inc (ATYR). have?

aTyr Pharma Inc (ATYR) has 56 emplpoyees as of January 10 2026.

What is aTyr Pharma Inc (ATYR) market cap?

Today ATYR has the market capitalization of 69.84M USD.